- Home
- STG vs CGEN Comparison
STG vs CGEN Comparison
Compare STG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- CGEN
- Stock Information
- Founded
- STG 2003
- CGEN 1993
- Country
- STG China
- CGEN Israel
- Employees
- STG N/A
- CGEN N/A
- Industry
- STG Other Consumer Services
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STG Real Estate
- CGEN Health Care
- Exchange
- STG Nasdaq
- CGEN Nasdaq
- Market Cap
- STG 112.4M
- CGEN 125.3M
- IPO Year
- STG 2018
- CGEN 2000
- Fundamental
- Price
- STG $7.01
- CGEN $1.88
- Analyst Decision
- STG
- CGEN
- Analyst Count
- STG 0
- CGEN 0
- Target Price
- STG N/A
- CGEN N/A
- AVG Volume (30 Days)
- STG 6.4K
- CGEN 565.5K
- Earning Date
- STG 11-21-2025
- CGEN 11-11-2025
- Dividend Yield
- STG N/A
- CGEN N/A
- EPS Growth
- STG N/A
- CGEN N/A
- EPS
- STG 3.59
- CGEN N/A
- Revenue
- STG $279,374,215.00
- CGEN $22,144,000.00
- Revenue This Year
- STG N/A
- CGEN N/A
- Revenue Next Year
- STG N/A
- CGEN $208.08
- P/E Ratio
- STG $2.05
- CGEN N/A
- Revenue Growth
- STG N/A
- CGEN N/A
- 52 Week Low
- STG $4.28
- CGEN $1.13
- 52 Week High
- STG $15.00
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- STG 33.73
- CGEN 57.00
- Support Level
- STG $7.28
- CGEN $1.30
- Resistance Level
- STG $8.53
- CGEN $2.38
- Average True Range (ATR)
- STG 0.29
- CGEN 0.18
- MACD
- STG -0.06
- CGEN 0.02
- Stochastic Oscillator
- STG 5.30
- CGEN 49.49
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.